Panelists discuss how chimeric antigen receptor (CAR) -T-cell therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma (R/R MM), demonstrating remarkable efficacy and offering new hope for patients with limited therapeutic options.
Panelists discuss how multiple myeloma care faces challenges including patient reluctance to seek treatment at academic centers, complex treatment landscapes, and the need for improved coordination between community and academic physicians.
Panelists discuss how collaborative care settings for multiple myeloma patients often lead to improved outcomes compared to non-collaborative approaches, citing factors such as access to specialized expertise, coordinated treatment plans, and comprehensive patient support.
Panelists discuss how streamlining the referral process for multiple myeloma patients can significantly reduce treatment initiation.
Panelists discuss how effective collaboration, care coordination, and communication between academic and community physicians are crucial for ensuring seamless transitions and high-quality care for patients with multiple myeloma.
Experts provide concluding insights on CAR-T cell therapy and offer their perspectives on the evolving treatment landscape for multiple myeloma, highlighting potential future directions and innovations in patient care.
A panel of experts examines the impact and potential of CAR T-cell therapy in earlier treatment lines for multiple myeloma, evaluating its efficacy, safety.
Multiple myeloma experts analyze recent developments in transplant-ineligible newly diagnosed multiple myeloma treatment, focusing on the latest updates presented at EHA 2024 and their potential impact on patient care.
Key opinion leaders evaluate the clinical implications of updated data presented at EHA 2024, interpreting how these findings may influence future treatment strategies in multiple myeloma.
Multiple myeloma specialists analyze recent findings presented at EHA 2024, offering expert perspectives on the PERSEUS and IsKIA clinical trials and their implications for patient care.
Medical experts explore the current standard of care and evolving treatment landscape for transplant eligible multiple myeloma, a complex hematological malignancy.
Amrita Y. Krishnan, MD, and Binod Dhakal, MD, discuss the clinical implications of data from MajesTEC-1 and provide key takeaways on the evolving relapsed/refractory multiple myeloma treatment landscape.
Following a review of recent data from MajesTEC-1 investigating teclistamab, the panel provides clinical insights on dosing and adverse event prophylaxis practices.
Experts on multiple myeloma review the study design and results from MajesTEC-1, focusing on the efficacy and safety findings, and provide insights on adverse event management practices.
Amrita Y. Krishnan, MD, and Binod Dhakal, MD, provide an overview of the current treatment landscape in relapsed/refractory multiple myeloma.
The panel concludes the discussion by offering future perspectives on the evolving treatment landscape in multiple myeloma, highlighting exciting developments and ongoing research.
Continuing discussion centered on a patient case, the panel discusses bispecific antibody combinations and the role of BCMA-targeting CAR T-cell therapies in relapsed/refractory multiple myeloma.
Adriana Rossi, MD, presents the case of a 60-year-old patient with stage III kappa light chain multiple myeloma, and members of the panel provide their initial impressions.
The panel discusses the utilization of CAR T-cell therapy for patients with multiple myeloma, highlighting treatment selection, sequencing, and insurance considerations.
Binod Dhakal, MD, presents the case of a 66-year-old patient with IgG kappa multiple myeloma, and the panel discusses treatment considerations and decisions.
Surbhi Sidana, MD, provides clinical insights on treatment sequencing strategies for patients with relapsed/refractory multiple myeloma.
Myeloma specialists discuss clinical trials investigating CAR T-cell therapies in patients with relapsed/refractory disease.
The panel discusses recent updates on bispecific antibodies for patients with relapsed/refractory multiple myeloma, highlighting studies investigating talquetamab, teclistamab, and elranatamab.
A panel of experts on multiple myeloma introduce themselves and discuss recent CAR T-cell therapy approvals in earlier treatment lines for patients with relapsed/refractory disease.
The panel closes by sharing final thoughts in the management of relapsed/refractory multiple myeloma, with a shared sense of optimism for advancements in treatment.
Key opinion leaders review the management of CAR-T therapy side effects in patients with relapsed/refractory multiple myeloma, including cytokine release syndrome and neurotoxicity, and emphasize the importance of early supervision and known toxicity timing.
Experts discuss the strategies and considerations for bridging therapy and the management of patients with relapsed/refractory multiple myeloma receiving CAR T-cell therapy.
Luciano Costa, MD, discusses the effectiveness and challenges of CAR-T therapy ciltacabtagene autoleucel for patients with multiple myeloma, emphasizing the response rates and duration and the advantages in early lines of treatment.
Dr Dhakal outlines the FDA-approved CAR T-cell therapy products for patients with multiple myeloma who have undergone at least four prior lines of treatment, emphasizing a focus on individualized decision-making when selecting patients for CAR-T.
Joselle Cook, M.B.B.S., presents the case of a 62-year-old woman with high-risk multiple myeloma to the panel for discussion.
